Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

The approval of bedaquiline (BDQ) for the treatment of tuberculosis has generated substantial interest in inhibiting energy metabolism as a therapeutic paradigm. However, it is not known precisely how BDQ triggers cell death in Mycobacterium tuberculosis (Mtb). Using (13)C isotopomer analysis, we sh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Mackenzie, Jared S., Lamprecht, Dirk A., Asmal, Rukaya, Adamson, John H., Borah, Khushboo, Beste, Dany J. V., Lee, Bei Shi, Pethe, Kevin, Rousseau, Simon, Krieger, Inna, Sacchettini, James C., Glasgow, Joel N., Steyn, Adrie J. C.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705017/
https://ncbi.nlm.nih.gov/pubmed/33257709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-19959-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados